

PRODUCT MONOGRAPH

Pr **ZERIT***

stavudine capsules USP, 15, 20, 30 and 40 mg

Antiretroviral Agent

Bristol-Myers Squibb Canada
Montreal, Canada

Date of Preparation:
March 14, 1996

* TM of Bristol-Myers Squibb Company used
under Licence by Bristol-Myers Squibb Canada

Date of Revision:
05 August, 2010

Control No.: 139228

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION 3

 SUMMARY PRODUCT INFORMATION 3

 INDICATIONS AND CLINICAL USE 3

 CONTRAINDICATIONS 3

 WARNINGS AND PRECAUTIONS 4

 ADVERSE REACTIONS 10

 DRUG INTERACTIONS 17

 DOSAGE AND ADMINISTRATION 18

 OVERDOSAGE 20

 ACTION AND CLINICAL PHARMACOLOGY 20

 STORAGE AND STABILITY 23

 DOSAGE FORMS, COMPOSITION AND PACKAGING 23

PART II: SCIENTIFIC INFORMATION 25

 PHARMACEUTICAL INFORMATION 25

 CLINICAL TRIALS 25

 DETAILED PHARMACOLOGY 26

 MICROBIOLOGY 30

 TOXICOLOGY 32

 REFERENCES 38

PART III: CONSUMER INFORMATION 40

 ABOUT THIS MEDICATION 40

 WARNINGS AND PRECAUTIONS 40

 INTERACTIONS WITH THIS MEDICATION 41

 PROPER USE OF THIS MEDICATION 41

 SIDE EFFECTS AND WHAT TO DO ABOUT THEM 41

 HOW TO STORE IT 42

 MORE INFORMATION 43

ZERIT

stavudine capsules USP, 15, 20, 30 and 40 mg

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients*
Oral	Capsules 15, 20, 30 and 40 mg	Lactose

* For a complete listing, see *Dosage Forms, Composition and Packaging* section

INDICATIONS AND CLINICAL USE

ZERIT (stavudine), in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection. (See CLINICAL TRIALS).

CONTRAINDICATIONS

ZERIT (stavudine) is contraindicated in patients with clinically significant hypersensitivity to stavudine or to any of the components contained in the formulation. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the Product Monograph.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

Lactic Acidosis/Severe Hepatomegaly with Steatosis/Hepatic Failure

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including stavudine and other antiretroviral agents. Although relative rates of lactic acidosis have not been assessed in prospective well-controlled trials, longitudinal cohort and retrospective studies suggest that this infrequent event may be more often associated with antiretroviral combinations containing stavudine. Female gender, obesity, and prolonged nucleoside exposure may be risk factors. Fatal lactic acidosis has been reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents. The combination of stavudine and didanosine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk (see WARNINGS AND PRECAUTIONS - Pregnancy).

Particular caution should be exercised when administering ZERIT to any patient with known risk factors for liver disease; however, cases of lactic acidosis have also been reported in patients with no known risk factors. Generalized fatigue, digestive symptoms (nausea, vomiting, abdominal pain, and sudden unexplained weight loss); respiratory symptoms (tachypnea and dyspnea); or neurologic symptoms (including motor weakness, see **Neurologic Symptoms**) might be indicative of the development of symptomatic hyperlactatemia or lactic acidosis syndrome. Symptoms associated with hyperlactatemia may continue or worsen following discontinuation of antiretroviral therapy.

Treatment with ZERIT should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).

An increased risk of hepatotoxicity may occur in patients treated with ZERIT in combination with didanosine and hydroxyurea compared to when ZERIT is used alone. Deaths attributed to hepatotoxicity have occurred in patients receiving this combination. Patients treated with this combination should be closely monitored for signs of liver toxicity.

Neurologic

Motor weakness (which was fatal in some cases) has been reported rarely in patients receiving combination antiretroviral therapy including ZERIT. Most of these cases occurred in the setting of symptomatic hyperlactatemia or lactic acidosis syndrome. The evolution of motor weakness may mimic the clinical presentation of Guillain-Barré syndrome (including respiratory failure). If motor weakness develops in a patient receiving ZERIT, the drug should be discontinued. Symptoms may continue or worsen following discontinuation of therapy.

Peripheral neuropathy, manifested by numbness, tingling, or pain in the hands or feet, has been reported in patients receiving ZERIT therapy. Peripheral neuropathy, which is dose related, has occurred more frequently in patients with advanced HIV disease, a history of neuropathy, or concurrent neurotoxic drug therapy, including didanosine (see ADVERSE REACTIONS).

Peripheral neuropathy, which was severe in some cases, has been reported in HIV-infected patients receiving hydroxyurea in combination with antiretroviral agents, including didanosine with or without stavudine.

Pancreatic

Fatal and nonfatal pancreatitis have occurred during therapy when ZERIT was part of a combination regimen that included didanosine or didanosine and hydroxyurea, in both treatment-naïve and treatment-experienced patients, regardless of degree of immunosuppression. This combination of ZERIT and didanosine and any other agents that are toxic to the pancreas should be suspended in patients with suspected pancreatitis. Reinstitution of ZERIT after a confirmed diagnosis of pancreatitis should be undertaken with particular caution and close patient monitoring. The new regimen should contain neither didanosine nor hydroxyurea.

General

Patients receiving ZERIT (stavudine) or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection and, therefore, should remain under close clinical observation by physicians experienced in the treatment of patients with HIV disease and associated complications.

Renal

In HIV-infected patients with renal impairment, renal clearance and apparent oral clearance of stavudine was decreased. The terminal elimination half-life ($t_{1/2}$) was prolonged up to 8 hours. C_{max} and T_{max} were not significantly affected by reduced renal function. Based on these preliminary observations, it is recommended that stavudine dosage be modified in patients with reduced creatinine clearance (≤ 50 mL/min) (see DOSAGE AND ADMINISTRATION).

Immune

Immune Reconstitution Syndrome: During the initial phase of treatment, patients responding to antiretroviral therapy may develop an inflammatory response to indolent or residual opportunistic infections (such as MAC, CMV, PCP, and TB), which may necessitate further evaluation and treatment.

Hepatic

Hepatitis or liver failure, which was fatal in some cases, have been reported with ZERIT. Hepatotoxicity and hepatic failure resulting in death were reported during postmarketing surveillance in HIV-infected patients treated with antiretroviral agents in combination with hydroxyurea. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. This combination should be avoided.

The safety and efficacy of ZERIT have not been established in patients with significant underlying liver disorders. During combination antiretroviral therapy, patients with preexisting liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities, including severe and potentially fatal hepatic adverse events, and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.

Fat Redistribution

Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy. In randomized controlled trials of treatment-naïve patients, clinical lipoatrophy or lipodystrophy developed in a higher proportion of patients treated with stavudine compared to other nucleosides (tenofovir or abacavir). Dual energy x-ray absorptiometry (DEXA) scans demonstrated overall limb fat loss in stavudine treated patients compared to limb fat gain or no change in patients treated with other nucleosides (abacavir, tenofovir or zidovudine). The incidence and severity of lipoatrophy or lipodystrophy are cumulative over time with stavudine-containing regimens. In clinical trials, switching from stavudine to other nucleosides (tenofovir or abacavir) resulted in increases in limb fat with modest to no improvements in clinical lipoatrophy. Given the potential risks of using ZERIT including lipoatrophy or lipodystrophy, a benefit-risk assessment for each patient should be made and an alternative antiretroviral carefully considered. Patients receiving ZERIT should be monitored for symptoms of lipoatrophy or lipodystrophy including a clinical examination to evaluate for physical signs of fat redistribution. Patients should be routinely questioned about body changes related to lipoatrophy or lipodystrophy.

Carcinogenesis, Mutagenesis, Impairment of Fertility

In 2-year carcinogenicity studies in mice and rats, stavudine was noncarcinogenic at doses which produced exposures (AUC) 39 and 168 times, respectively, human exposure at the recommended clinical dose. Benign and malignant liver tumors in mice and rats and malignant urinary bladder tumors in male rats occurred at levels of exposure 250 (mice) and 732 (rats) times human exposure at the recommended clinical dose.

Stavudine was not mutagenic in the Ames, *E. coli* reverse mutation, or the CHO/HGPRT mammalian cell forward gene mutation assays, with and without metabolic activation. Stavudine produced positive results in the in vitro human lymphocyte clastogenesis and mouse fibroblast assays, and in the in vivo mouse micronucleus test. In the in vitro assays, stavudine

elevated the frequency of chromosome aberrations in human lymphocytes (concentrations of 25 to 250 µg/mL, without metabolic activation) and increased the frequency of transformed foci in mouse fibroblast cells (concentrations of 25 to 2500 µg/mL, with and without metabolic activation). In the in vivo micronucleus assay, stavudine was clastogenic in bone marrow cells following oral stavudine administration to mice at dosages of 600 to 2000 mg/kg/day for 3 days.

No evidence of impaired fertility was seen in rats with exposures (based on C_{max}) up to 216 times that observed following a clinical dosage of 1 mg/kg/day.

Special Populations

Pregnant Women

There are no adequate and well-controlled studies of stavudine in pregnant women. Stavudine should be used during pregnancy only if the potential benefit justifies the potential risk.

Fatal lactic acidosis has been reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents. It is not known if pregnancy augments the risk of lactic acidosis/hepatic steatosis syndrome reported in nonpregnant individuals receiving nucleoside analogues (see WARNINGS AND PRECAUTIONS - Lactic Acidosis / Severe Hepatomegaly with Steatosis / Hepatic Failure). **The combination of stavudine and didanosine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk.** Health care providers caring for HIV-infected pregnant women receiving stavudine should be alert for early diagnosis of lactic acidosis/hepatic steatosis syndrome.

Reproduction studies have been performed in rats and rabbits with exposures (based on C_{max}) up to 399 and 183 times, respectively, of that seen at a clinical dosage of 1 mg/kg/day and have revealed no evidence of teratogenicity or impaired fertility. A slight post-implantation loss was noted at 216 times the human exposure with no effect noted at approximately 135 times the human exposure. The incidence in fetuses of a common skeletal variation, unossified or incomplete ossification of sternebra, was increased in rats at 399 times human exposure while no effect was observed at 216 times human exposure. An increase in early rat neonatal mortality (birth to 4 days of age) occurred at 399 times the human exposure, while survival of neonates was unaffected at approximately 135 times the human exposure. A study in rats showed that stavudine is transferred to the fetus through the placenta. The concentration in fetal tissue was approximately one-half the concentration in maternal plasma. Stavudine has been shown to cross the human placenta in an *ex vivo* term model. Animal reproduction studies are not always predictive of human response.

Nursing Women

Studies in which lactating rats were administered a single dose (5 or 100 mg/kg) of stavudine demonstrated that stavudine is readily excreted into breast milk.

Although it is not known whether ZERIT is excreted in human milk, there exists the potential for adverse effects from stavudine in nursing infants. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, **mothers should be instructed not to breast-feed if they are receiving ZERIT.**

Pediatrics

The safety and effectiveness of ZERIT have been established in pediatric patients supported by evidence from adequate and well-controlled studies of stavudine in adults with additional data concerning safety and pharmacokinetics in pediatric patients.

Patients should be monitored for clinically significant elevations of hepatic transaminases. If these elevations develop on treatment, ZERIT therapy should be interrupted. If the hepatic transaminase values return to pretherapy levels, resumption of treatment may be considered using a dosage schedule of 1 mg/kg/day, not to exceed the recommended adult dose of 20 mg twice daily.

One open-label, phase I trial enrolled 38 subjects aged 5 weeks to 15 years; 9 had received no prior antiretroviral therapy and 29 had received zidovudine for a median duration of 104 weeks. Patients in this trial received ZERIT in initial doses ranging from 0.125 to 4.0 mg/kg/day with an average dose of 1.7 mg/kg/day for a median duration of 84 weeks (range 8 - 140 weeks). A second open-label trial, initiated to provide stavudine for children who had failed or were intolerant of alternative antiretroviral therapy, enrolled 51 subjects aged 8 months to 18 years who had received prolonged zidovudine and didanosine. These patients were treated with ZERIT at a dose of 2 mg/kg/day, for a median duration of 33 weeks (range 2 days - 82 weeks).

A multi-centre, randomized, double-blind trial (Study ACTG 240) evaluated ZERIT [d4t] (2 mg/kg/day) versus zidovudine [ZDV] (200 mg QID) in the treatment of HIV-infected pediatric patients who had received ≤ 6 weeks of prior antiretroviral therapy. Two hundred and sixteen subjects, with a median baseline CD4 cell count of 1000 cells/mm³, were enrolled. CD4 cell counts were better maintained on ZERIT treatment as compared with ZDV ($p < 0.05$). Patients on ZDV experienced more neutropenia (19%) versus patients on ZERIT (7%) ($p < 0.01$). No differences were observed in any other laboratory parameters, signs or symptoms.

Geriatrics

Clinical studies of ZERIT did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently than younger patients. Greater sensitivity of some older individuals to the effects of ZERIT cannot be ruled out.

In a monotherapy Expanded Access Program for patients with advanced HIV infection, peripheral neuropathy or peripheral neuropathic symptoms were observed in 15 of 40 (38%) elderly patients receiving 40 mg BID and 8 of 51 (16%) elderly patients receiving 20 mg BID. Of the approximately 12,000 patients enrolled in the Expanded Access Program, peripheral neuropathy or peripheral neuropathic symptoms developed in 30% of patients receiving 40 mg BID and 25% of patients receiving 20 mg BID. Elderly patients should be closely monitored for

signs and symptoms of peripheral neuropathy.

Stavudine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function. Dose adjustment is recommended for patients with renal impairment (see DOSAGE AND ADMINISTRATION - Dosage Adjustment).

Lactose Intolerance

Zerit capsules contain lactose (120 and 240 mg depending on capsule strength). This amount is probably insufficient to induce specific symptoms of intolerance.

Monitoring and Laboratory Tests

Complete blood counts and clinical laboratory tests should be performed prior to initiating ZERIT therapy and at appropriate intervals thereafter.

Moderate elevations of mean corpuscular volume may be observed in patients taking ZERIT and may provide an indication of treatment compliance.

ADVERSE REACTIONS

Adult Patients

Adverse Drug Event Overview

A total of 202 patients in two clinical studies were treated with combination therapy that included stavudine in the regimen. The most clinically relevant serious adverse events, regardless of relationship to study treatment in these two clinical studies, included lactic acidosis, pancreatitis, hepatic dysfunction and peripheral neuropathy.

The most common adverse events in the stavudine-containing regimens of the combination therapy clinical studies, regardless of grade or relationship to study treatment, included asthenia, diarrhea, dry skin, headache, increased cough, nausea, pharyngitis, rash and vomiting. In total, 31 out of the 202 patients in the stavudine-containing regimens from these two clinical studies, discontinued study medication due to adverse events.

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse drug reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Many of the serious clinical adverse events reported from patients receiving stavudine in clinical trials were consistent with the course of HIV infection. Concurrent therapy with other medications was permitted in these trials. Therefore, it is difficult to distinguish which events were related to stavudine, the disease itself, or other therapies.

When ZERIT is used in combination with other agents with similar toxicities, the incidence of adverse events may be higher than when ZERIT is used alone. Pancreatitis, peripheral neuropathy, and liver function abnormalities occur more frequently in patients treated with the combination of ZERIT and didanosine.

Fatal pancreatitis and hepatotoxicity may occur more frequently in patients treated with ZERIT in combination with didanosine and hydroxyurea (see WARNINGS and PRECAUTIONS).

Lactic Acidosis

Fatal lactic acidosis has occurred in patients treated with ZERIT in combination with other antiretroviral agents. Patients with suspected lactic acidosis should immediately suspend therapy with ZERIT. Permanent discontinuation of ZERIT should be considered for patients with confirmed lactic acidosis.

Peripheral Neuropathy

ZERIT therapy has rarely been associated with motor weakness, occurring predominantly in the setting of lactic acidosis. If motor weakness develops, ZERIT should be discontinued.

ZERIT (stavudine) therapy has also been associated with peripheral sensory neuropathy, which can be severe, is dose related, and occurs more frequently in patients being treated with neurotoxic drug therapy, including didanosine, in patients with advanced HIV infection, or in patients who have previously experienced peripheral neuropathy.

Patients should be monitored for the development of neuropathy, which is usually manifested by numbness, tingling, or pain in the feet or hands. Stavudine-related peripheral neuropathy may resolve if therapy is withdrawn promptly. In some cases, symptoms may worsen temporarily following discontinuation of therapy. If symptoms resolve completely, patients may tolerate resumption of treatment at one-half the dose (see DOSAGE AND ADMINISTRATION). If neuropathy recurs after resumption of ZERIT, permanent discontinuation of ZERIT should be considered.

Pancreatitis

Pancreatitis resulting in death was observed in patients treated with ZERIT plus didanosine, with or without hydroxyurea, in controlled clinical studies and in postmarketing reports.

Pancreatitis was generally attributed to advanced disease or to prior or concurrent treatment with medications known to be associated with pancreatitis. The occurrences were not dose-related, and were occasionally fatal. Patients with a history of pancreatitis appear to be at increased risk for recurrence (see WARNINGS AND PRECAUTIONS).

**Clinical Adverse Events^a in START 1^b Studies
with a frequency of > 5% in at least one treatment group
(Combination Therapy)**

Adverse Events	Percent of Patients	
	START 1	
	ZERIT + lamivudine + indinavir n = 100 ^c	zidovudine + lamivudine + indinavir n = 102
Digestive System		
Nausea	43	63
Diarrhea	34	16
Vomiting	18	33
Pain Abdomen	21	14
Dyspepsia	5	8
Anorexia	12	9
Disorder Gastrointestinal	3	9
Body as a Whole		
Asthenia	25	26
Headache	25	26
Pain Back	23	20
Infection	17	16
Fever	14	11
Pain	15	9
Flu Syndrome	8	6
Accidental Injury	6	6
Infection Fungal	7	5
Chills	7	1
Respiratory System		
Pharyngitis	28	24
Cough Increased	21	16
Rhinitis	18	6
Sinusitis	13	7
Bronchitis	6	7
Skin/Appendages		
Rash	18	13
Dry Skin	11	12
Acne	5	6
Nervous System		

Adverse Events	Percent of Patients	
	START 1	
	ZERIT + lamivudine + indinavir n = 100 ^c	zidovudine + lamivudine + indinavir n = 102
Peripheral Neurologic Symptoms/Neuropathy	8	7
Depression	8	12
Insomnia	6	9
Dizziness	5	7
Metabolic/Nutritional System		
Bilirubinemia	9	4
Weight Decreased	4	8
Urogenital System		
Dysuria	9	6
Hematuria	10	4
Calculus Kidney	7	5
Special Senses		
Taste Perversion	6	10
Conjunctivitis	6	4
Musculoskeletal System		
Arthralgia	7	5
Myalgia	7	2

^a Any severity, regardless of relationship to study regimen.

^b START 1 compared triple combination regimens in 202 treatment-naive patients. Patients received either ZERIT (40 mg BID) plus lamivudine plus indinavir or zidovudine plus lamivudine plus indinavir.

^c Duration of stavudine therapy = 48 weeks.

**Clinical Adverse Events^a in START 2^b Studies
with a frequency of > 5% in at least one treatment group
(Combination Therapy)**

Adverse Events	Percent of Patients	
	START 2	
	ZERIT + didanosine + indinavir n = 102 ^c	zidovudine + lamivudine + indinavir n = 103
Digestive System		
Nausea	53	67
Diarrhea	45	39
Vomiting	30	35
Pain Abdomen	20	24
Flatulence	14	14
Dyspepsia	10	11
Anorexia	7	12
Dry Mouth	8	6
Eructation	4	8
Constipation	4	7
Ulcer Mouth	6	4
Body as a Whole		
Asthenia	32	38
Headache	46	37
Pain Back	11	13
Infection	23	18
Fever	20	8
Pain	17	24
Flu Syndrome	10	8
Accidental Injury	6	8
Infection Fungal	6	5
Chills	7	5
Lesion	3	6
Respiratory System		
Pharyngitis	37	28
Cough Increased	27	20
Rhinitis	22	16
Sinusitis	17	7
Respiratory System (con't)		

Adverse Events	Percent of Patients	
	START 2	
	ZERIT + didanosine + indinavir n = 102 ^c	zidovudine + lamivudine + indinavir n = 103
Bronchitis	3	6
Disorder Lung	6	0
Skin/Appendages		
Rash	30	18
Dry Skin	33	23
Acne	6	2
Pruritus	13	11
Sweating	9	6
Nervous System		
Peripheral Neurologic Symptoms/Neuropathy	21	10
Depression	12	12
Insomnia	7	4
Dizziness	11	9
Metabolic/Nutritional System		
Bilirubinemia	7	3
Urogenital System		
Dysuria	2	6
Hematuria	7	8
Infection Urinary Tract	4	7
Special Senses		
Taste Perversion	12	21
Musculoskeletal System		
Arthralgia	9	12
Myalgia	10	6

^a Any severity, regardless of relationship to study regimen.

^b START 2 compared two triple-combination regimens in 205 treatment-naive patients. Patients received either ZERIT (40 mg BID) plus didanosine plus indinavir or zidovudine plus lamivudine plus indinavir.

^c Duration of stavudine therapy = 48 weeks.

Laboratory Abnormalities

Selected laboratory abnormalities reported in two controlled combination studies are provided in the following tables.

Selected Laboratory Abnormalities in START 1 and START 2 Studies (Grades 3-4)

Parameter	Percent of Patients			
	START 1		START 2	
	ZERIT + lamivudine + indinavir n = 100	zidovudine + lamivudine + indinavir n = 102	ZERIT + didanosine + indinavir n = 102	zidovudine + lamivudine + indinavir n = 103
Bilirubin (> 2.6 x ULN)	7	6	16	8
AST (SGOT) (> 5 x ULN)	5	2	7	7
ALT (SGPT) (> 5 X ULN)	6	2	8	5
GGT (> 5 X ULN)	2	2	5	2
Lipase (> 2 x ULN)	6	3	5	5
Amylase (> 2 x ULN)	4	< 1	8	2

ULN = upper limit of normal

Selected Laboratory Abnormalities in START 1 and START 2 Studies (All Grades)

Parameter	Percent of Patients			
	START 1		START 2	
	ZERIT + lamivudine + indinavir n = 100	zidovudine + lamivudine + indinavir n = 102	ZERIT + didanosine + indinavir n = 102	zidovudine + lamivudine + indinavir n = 103
Total Bilirubin	65	60	68	55
AST (SGOT)	42	20	53	20
ALT (SGPT)	40	20	50	18
GGT	15	8	28	12
Lipase	27	12	26	19
Amylase	21	19	31	17

Post-Market Adverse Drug Reactions

The following events have been identified during post-approval use of ZERIT. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to their seriousness, frequency of reporting, causal connection to ZERIT, or a combination of these factors.

Body as a Whole: abdominal pain, allergic reactions, chills/fever, redistribution/accumulation of body fat, lipoatrophy / lipodystrophy (see WARNINGS AND PRECAUTIONS, Fat Redistribution).

Digestive Disorders:	anorexia.
Exocrine Gland Disorders:	pancreatitis [including fatal cases (see WARNINGS AND PRECAUTIONS)].
Hematologic Disorders:	anemia, neutropenia, leukopenia, macrocytosis, and thrombocytopenia.
Liver	lactic acidosis and hepatic steatosis [including fatal cases (see WARNINGS AND PRECAUTIONS)], hepatitis and liver failure [including fatal cases (see WARNINGS AND PRECAUTIONS)].
Metabolic Disorders:	diabetes mellitus, hyperglycemia.
Musculoskeletal:	myalgia.
Nervous system:	insomnia, severe motor weakness (most often reported in the setting of symptomatic hyperlactatemia or lactic acidosis, including fatal cases, see WARNINGS AND PRECAUTIONS).

Pediatric Patients

Adverse reactions and serious laboratory abnormalities in pediatric patients were similar in type and frequency to those seen in adult patients.

DRUG INTERACTIONS

Drug-Drug Interactions

Zidovudine may competitively inhibit the intracellular phosphorylation of stavudine (see ACTIONS and CLINICAL PHARMACOLOGY). Therefore, use of zidovudine in combination with ZERIT is not recommended. In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin; therefore coadministration of stavudine with either doxorubicin or ribavirin should be undertaken with caution.

No pharmacokinetic interactions were observed between ZERIT and didanosine, lamivudine (3TC), or nelfinavir when co-administered in clinical trials.

Stavudine does not inhibit the major cytochrome P450 isoforms CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4; therefore, it is unlikely that clinically significant drug interactions will occur with drugs metabolized through these pathways.

Drug-Food Interactions

ZERIT (stavudine) may be taken without regard to meals. Absorption of stavudine was assessed in a study of 16 asymptomatic HIV-infected patients. Each patient received a 70 mg

oral dose of ZERIT in the fasting state, 1 hour before a standardized meal, and immediately after a standardized meal. The results indicate that systemic exposure to stavudine is not reduced when ZERIT is taken with food. Although the rate of absorption decreased, the extent of absorption was not significantly ($p = 0.27$) affected by the presence of food when ZERIT was taken immediately after a meal. Mean (\pm SD) C_{MAX} of stavudine was reduced from 1.44 (\pm 0.49) $\mu\text{g/mL}$ in the fasting state to 0.75 (\pm 0.16) $\mu\text{g/mL}$ after a meal, and the median time to achieve C_{MAX} was prolonged from 0.6 to 1.5 hours. However, mean (\pm SD) $AUC_{0-\infty}$ values were 2.50 (\pm 0.71) $\mu\text{g}\cdot\text{hr/mL}$ and 2.31 (\pm 0.55) $\mu\text{g}\cdot\text{hr/mL}$ in the fasting state and after a meal, respectively, indicating that systemic exposure was similar with or without the presence of food.

Drug-Herb Interactions

Interactions with herbs have not been established.

DOSAGE AND ADMINISTRATION

Recommended Dose and Dosage Adjustment

Adults

The interval between oral doses should be 12 hours. ZERIT (stavudine) may be taken with or without food. The recommended doses are based on body weight, as outlined in the following table:

Adult dosing

Patient weight	ZERIT Dosage
< 60 kg	30 mg bid
\geq 60 kg	40 mg bid

Dosage Adjustment

Renal Impairment

Adults

The following dose adjustments are recommended in adult patients with renal impairment.

Recommended ZERIT Dosing Modifications for Subjects with Renal Impairment		
Creatinine Clearance (mL/min)	Recommended ZERIT Dose by Patient Weight	
	≥ 60 kg	< 60 kg
> 50 *	40 mg every 12 hours*	30 mg every 12 hours *
26 - 50	20 mg every 12 hours	15 mg every 12 hours
<25 †	20 mg every 24 hours	15 mg every 24 hours

* Normal dose, no adjustment necessary.

† For patients undergoing hemodialysis, the daily dose of ZERIT should be administered after the completion of a scheduled hemodialysis session. On nondialysis days, ZERIT should be administered at the same time of day as it is on dialysis days.

Hepatic Impairment

Adults

Dosing adjustment is not necessary in subjects with stable hepatic impairment. In the event of rapidly elevating aminotransferase levels, treatment with ZERIT should be suspended.

Peripheral Neuropathy

Clinical symptoms of peripheral neuropathy which is usually characterized by numbness, tingling or pain in the feet or hands should prompt interruption of ZERIT treatment and evaluation of the patient. These symptoms may be difficult to detect in children (see WARNINGS AND PRECAUTIONS). If symptoms develop, ZERIT should be interrupted. Symptoms may resolve if therapy is withdrawn promptly. Some patients may experience a temporary worsening of symptoms following discontinuation of therapy. If symptoms resolve completely, resumption of treatment may be considered. If a reduced dose is warranted, use one-half the recommended dose.

OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre.

There is no known antidote for ZERIT (stavudine) overdose. Experience with adults treated with 12 to 24 times the recommended daily dosage revealed no acute toxicity. Patients may benefit from administration of activated charcoal. Stavudine can be removed by hemodialysis, the mean \pm SD hemodialysis clearance of stavudine is 120 ± 18 mL/min. It is not known whether stavudine is eliminated by peritoneal dialysis.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

ZERIT (stavudine), also known as d4T, is a synthetic thymidine nucleoside analogue active against the Human Immunodeficiency Virus (HIV).

In vitro studies demonstrate that stavudine is converted to the triphosphate by cellular kinases. The 5'-triphosphate is the active form of the drug. In cell culture studies with two different cell lines, stavudine triphosphate had an intracellular half-life of 3.5 hours. Stavudine triphosphate has been shown to be a potent competitive inhibitor of HIV reverse transcriptase ($k_i = 0.0083$ to $0.032 \mu\text{M}$). In addition, both stavudine triphosphate and the natural substrate, thymidine triphosphate, are used by HIV reverse transcriptase *in vitro* for incorporation into the nascent DNA chain. Stavudine lacks the 3'-hydroxyl group necessary for DNA elongation and once incorporated into DNA, functions as a DNA chain terminator *in vitro*. Both the inhibition of binding of thymidine triphosphate to reverse transcriptase and DNA chain termination may be partially responsible for inhibition of HIV replication *in vitro*. In addition to the inhibitory effect on HIV reverse transcriptase, stavudine triphosphate exhibits some inhibitory effect on DNA polymerase beta and gamma, and markedly reduces the syntheses of mitochondrial DNA.

Clinically, ZERIT has been studied in various combinations with other classes of anti-retroviral drugs, including didanosine, lamivudine (3TC), ritonavir, nelfinavir, saquinavir, indinavir, and hydroxyurea (see PHARMACOLOGY - Clinical Studies). However, zidovudine in combination with ZERIT is not recommended (see WARNINGS AND PRECAUTIONS - Drug Interactions). Both drugs are phosphorylated by the same cellular enzyme (thymidine kinase), which may preferentially phosphorylate zidovudine, thereby decreasing the phosphorylation of stavudine to its active triphosphate form.

Based on *in vitro* testing, the activation of stavudine has also been shown to be inhibited by other drugs. Among the several drugs tested, the only ones that may interfere with stavudine phosphorylation at relevant concentrations are doxorubicin and ribavirin, but not other drugs used in the therapy of HIV infection which are similarly phosphorylated. The clinical significance of this is unknown.

Clinical trials supporting the use of ZERIT in appropriate antiretroviral regimens for the treatment of HIV-infected patients, demonstrated, overall, greatest inhibition of HIV RNA levels and greatest increase in CD4 cell counts with triple-combination regimens (see PHARMACOLOGY - Clinical Studies).

Drug Resistance

HIV isolates with reduced susceptibility to stavudine have been selected *in vitro* and were also obtained from patients treated with stavudine. Phenotypic analysis of HIV-1 isolates from 61 patients receiving prolonged (6-29 months) stavudine monotherapy showed that post-therapy isolates from four patients exhibited EC_{50} values more than 4-fold (range 7- to 16-fold) higher

than the average pretreatment susceptibility of baseline isolates. Of these, HIV-1 isolates from one patient contained the zidovudine-resistance-associated mutation T215Y and K219E, and isolates from another patient contained the multiple-nucleoside- resistance-associated mutation Q151M. Mutations in the RT gene of HIV-1 isolates from the other two patients were not detected. The genetic basis for stavudine susceptibility changes has not been identified.

Cross-resistance

Cross-resistance among HIV-1 reverse transcriptase inhibitors has been observed. Five of 11 stavudine post-treatment isolates developed moderate resistance to zidovudine (9- to 176-fold) and 3 of those 11 isolates developed moderate resistance to didanosine (7- to 29-fold). Several studies have demonstrated that prolonged stavudine treatment can select and /or maintain thymidine analogue mutations (TAMs) associated with zidovudine resistance. The decrease of susceptibility in cell culture is subtle requiring two or more TAMs (generally M41L and T215Y) before stavudine susceptibility is decreased (> 1.5 fold). These TAMs are seen at a similar frequency with stavudine and zidovudine in virological treatment. The clinical relevance of these findings suggests that stavudine should be avoided in the presence of thymidine analogue mutations, especially M41L and T215Y .

Pharmacokinetics in Adults

The pharmacokinetics of stavudine have been evaluated in HIV-infected adult and pediatric patients (refer to table below). Peak plasma concentrations (C_{max}) and area under the plasma concentration-time curve (AUC) increased in proportion to dose after both single and multiple doses ranging from 0.03 to 4 mg/kg. There was no significant accumulation of stavudine with repeated administration every 6, 8, or 12 hours.

Mean ± SD Pharmacokinetic Parameters of Stavudine in Adult and Pediatric HIV-Infected Patient

Parameter	Adult Patients	n	Pediatric Patients	n
Oral bioavailability (F)	86.4 ± 18.2%	25	76.9 ± 31.7%	20
Volume of distribution ^a (VD)	58 ± 21 L	44	18.5 ± 9.2 L/m ²	21
Apparent oral volume of distribution ^b (VD/F)	66 ± 22 L	71	not determined	-
Ratio of CSF: plasma concentrations (as %) ^c	not determined	-	59 ± 35%	8
Total body clearance ^a (CL)	8.2 ± 2.3 mL/min/kg	44	247 ± 94 mL/min/m ²	21
Apparent oral clearance ^b (CL/F)	8.0 ± 2.6 mL/min/kg	113	333 ± 87 mL/min/m ²	20
Elimination half-life (T _{1/2}), IV dose ^a	1.15 ± 0.35 h	44	1.11 ± 0.28 h	21
Elimination half-life (T _{1/2}), oral dose ^b	1.44 ± 0.30 h	115	0.96 ± 0.26 h	20
Urinary recovery of stavudine (% of dose)	39 ± 23%	88	34 ± 16%	19

^a following 1 hour IV infusion

^b following single oral dose

^c following multiple oral doses

Absorption

Following oral administration, stavudine is rapidly absorbed, with peak plasma concentrations occurring within 1 hour after dosing. The systemic exposure to stavudine is the same following administration as capsules or solution.

Distribution

Binding of stavudine to serum proteins was negligible over the concentration range of 0.01 to 11.4 µg/mL. Stavudine distributes equally between red blood cells and plasma.

Metabolism

The metabolic fate of stavudine has not been elucidated in humans.

Excretion

Renal elimination accounted for about 40% of the overall clearance regardless of the route of administration. The mean renal clearance was about twice the average endogenous creatinine clearance, indicating active tubular secretion in addition to glomerular filtration.

STORAGE AND STABILITY

ZERIT capsules should be stored at room temperature (15° to 30°C) and protected from excessive moisture. Keep bottles tightly closed.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Capsules

ZERIT (stavudine) is available as capsules containing:

- ° 15 mg of stavudine - light yellow and dark red capsule imprinted with "BMS 1964" and "15";
- ° 20 mg of stavudine - light brown capsule imprinted with "BMS 1965" and "20";
- ° 30 mg of stavudine - light orange and dark orange capsule imprinted with "BMS 1966" and "30"
- ° 40 mg of stavudine - dark orange capsule imprinted with "BMS 1967" and "40"

ZERIT capsules are available in bottles of 60.

Composition


ZERIT (stavudine) capsules are available for oral administration in strengths of 5, 15, 20, 30 and 40 mg of stavudine. Non medicinal ingredients: lactose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate. Capsule shell: gelatin, black iron oxide (20 mg only), printing ink, silicon dioxide, sodium lauryl sulphate, titanium dioxide and yellow and red iron oxides.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name:	Stavudine
Chemical name:	2',3'-didehydro-3'-deoxythymidine
Molecular formula:	C ₁₀ H ₁₂ N ₂ O ₄
Molecular mass:	224.2 daltons
Structural formula:	



Physicochemical properties: Stavudine is a white to off-white crystalline solid. The solubility of stavudine at 23°C is approximately 87 mg/mL in water, 29 mg/mL in methanol, 30 mg/mL in propylene glycol, and 19 mg/mL in ethanol.

CLINICAL TRIALS

The following clinical trials support the use of ZERIT in appropriate antiretroviral regimens for the treatment of HIV-infected patients. Overall, greatest inhibition of HIV RNA levels and greatest increase in CD4 cell counts were observed with triple-combination regimens.

Combination Therapy

The START-1 study was a multi-center, randomized, open-label combination therapy trial of ZERIT [d4T] (40 mg BID) plus lamivudine [3TC] (150 mg BID) plus indinavir [IDV] (800 mg TID) versus zidovudine [ZDV] (200 mg TID) plus 3TC (150 mg BID) plus IDV (800 mg TID) for the treatment of HIV-infected adults with CD4 counts of ≥ 200 cells/mm³ and a plasma HIV-RNA baseline copy number of ≥ 5000 copies/mL who had received no prior antiretroviral treatment. The study enrolled a total of 200 subjects. The median baseline CD4 cell count was 400 cells/mm³ and the baseline median viral load was 4.6 log₁₀ copies/mL.

Efficacy Endpoint Results: START 1

	Analysis Time Point (wks)	CD4 Mean Change from Baseline (cells/mm ³) (range), p value*	HIV-RNA Mean Change from Baseline (log ₁₀ copies/mL) (range), p value*
START 1			
ZERIT + lamivudine + indinavir	24	+ 161 (-124, +530), p=0.42	-1.81 (-0.36, -3.06), p=0.35
	48	+ 237 (-142, +722), p=0.39	-1.86 (-0.64, -3.06), p=0.28
zidovudine + lamivudine + indinavir	24	+ 148 (-208, +650)	-1.63 (-0.09, -3.07)
	48	+ 207 (-250, +566)	-1.63 (0.19, -3.07)

* p values for comparison between treatments from Wilcoxon 2-sample test, stratified by investigational site.

DETAILED CLINICAL PHARMACOLOGY

Pharmacokinetics in Adults

The pharmacokinetics of stavudine have been evaluated in 119 HIV-infected patients following the administration of oral doses ranging from 0.03 to 4 mg/kg administered as single doses and as multiple doses every 6, 8 or 12 hours. Stavudine pharmacokinetics have also been evaluated in 44 HIV-infected patients after single intravenous doses ranging from 0.0625 to 1 mg/kg administered as 1-hour infusions.

Absorption and Bioavailability in Adults

Following oral administration to HIV-infected patients, stavudine was rapidly absorbed with peak plasma concentrations occurring within 1 hour after dosing and a mean absolute bioavailability of 90.7% (n = 25). Peak plasma concentrations (C_{MAX}) increased in a dose-related manner for doses (n = 4 to 10 per dose level) ranging from 0.03 to 4 mg/kg. Mean (± SD) C_{MAX} values ranged from 0.03 (± 0.01) to 4.19 (± 1.73) µg/mL, respectively, occurring ≤ 1 hour after dosing. Plasma concentrations declined to ≤ 10% of mean C_{MAX} values by 5 to 8 hours postdose. Mean values for the area under the plasma concentration-time curve (AUC) were proportional to dose, both after single doses and at steady state. Mean (± SD) AUC values ranged from 0.05 (± 0.02) to 7.08 (± 1.12) µg·hr/mL, respectively. There was no significant accumulation of stavudine with repeated administration every 6, 8 or 12 hours.

Effect of Food on Oral Absorption in Adults

ZERIT (stavudine) may be taken without regard to meals. Absorption of stavudine was assessed in a study of 16 asymptomatic HIV-infected patients. Each patient received a 70 mg oral dose of ZERIT in the fasting state, 1 hour before a standardized meal, and immediately after a standardized meal. The results indicate that systemic exposure to stavudine is not reduced when ZERIT is taken with food. Although the rate of absorption decreased, the extent of absorption was not significantly ($p = 0.27$) affected by the presence of food when ZERIT was taken immediately after a meal. Mean (\pm SD) C_{MAX} of stavudine was reduced from 1.44 (\pm 0.49) $\mu\text{g/mL}$ in the fasting state to 0.75 (\pm 0.16) $\mu\text{g/mL}$ after a meal, and the median time to achieve C_{MAX} was prolonged from 0.6 to 1.5 hours. However, mean (\pm SD) $AUC_{0-\infty}$ values were 2.50 (\pm 0.71) $\mu\text{g}\cdot\text{hr/mL}$ and 2.31 (\pm 0.55) $\mu\text{g}\cdot\text{hr/mL}$ in the fasting state and after a meal, respectively, indicating that systemic exposure was similar with or without the presence of food.

Distribution in Adults

Following intravenous infusions ($n = 44$) of stavudine at doses ranging from 0.0625 to 1 mg/kg, mean (\pm SD) values for volume of distribution were independent of dose and ranged from 28.4 (\pm 5.9) to 81.2 (\pm 41.7) L, suggesting that stavudine distributes into extravascular spaces. Mean (\pm SD) values for apparent volume of distribution following oral administration of doses ($n = 110$) ranging from 0.03 to 4 mg/kg were also independent of dose, and ranged from 42.2 (\pm 8.3) to 81.0 (\pm 21.7) L. Volume of distribution did not correlate with body weight.

Binding of stavudine to serum proteins was negligible over the concentration range of 0.01 - 11.4 $\mu\text{g/mL}$. Stavudine distributes equally between red blood cells and plasma.

Cerebrospinal fluid concentrations were determined in three subjects. Following oral doses of 1.33, 3.00 and 4.00 mg/kg, stavudine concentration in cerebrospinal fluid was 0.08, 0.20 and 0.48 $\mu\text{g/mL}$ at 0.5, 1.75 and 5.0 hours after dosing.

Elimination in Adults

Values for plasma clearance and terminal elimination half-life were found to be independent of dose administered over an intravenous dosing range of 0.0625 to 1 mg/kg and an oral dosing range of 0.03 to 4 mg/kg. Following 1-hour infusions ($n = 44$), plasma concentration of stavudine declined in a biphasic manner with mean (\pm SD) terminal elimination half-life values ranging from 0.86 (\pm 0.20) to 1.27 (\pm 0.59) hours. After oral doses ($n = 110$), mean (\pm SD) terminal half-life estimates ranged from 1.03 (\pm 0.16) to 1.59 (\pm 0.34) hours. Within studies intrapatient variability of terminal half-life was 12% to 17%, and interpatient variability was 15% to 27%. Mean (\pm SD) total body clearance values after intravenous infusion ranged from 417 (\pm 78) to 764 (\pm 261) mL/min, and were independent of dose administered and of body weight. Following oral administration, mean (\pm SD) apparent oral clearance values were independent of dose and ranged from 441 (\pm 47) to 771 (\pm 345) mL/min, with intrapatient variability of 10% to 11% and interpatient variability of 13% to 44% among studies. About 40% of total clearance was by renal elimination, regardless of the route of administration. The mean renal clearance of stavudine is about twice the average endogenous creatinine clearance,

indicating active tubular secretion in addition to glomerular filtration. Mean (\pm SD) cumulative urinary excretion of unchanged drug over 12 to 24 hours after administration of an oral dose ranged from 22.9% (\pm 3.7%) to 58.7% (\pm 22.2%) of the dose. Nonrenal clearance is presumed to be due to intracellular metabolism to the mono-, di-, and triphosphates, or intracellular cleavage to thymine and uptake by pyrimidine salvage pathways. In studies of [5-³H] stavudine and [4-¹⁴C] stavudine in nonhuman primates, biliary excretion of stavudine appeared to be negligible, with radioactivity in feces accounting for < 1% of an administered dose after either oral or intravenous administration.

The protein binding of stavudine *in vitro* is negligible; therefore, drug interactions involving binding site displacement are not anticipated.

Metabolism in Adults

The metabolic fate of stavudine has not been elucidated in humans. When stavudine was incubated with human liver slices for six hours, 87 percent of radioactivity was accounted for by parent compound, 2 percent was metabolized to thymine and 7 percent was associated with unidentified polar compounds.

Comparative pharmacokinetic studies of stavudine in humans and nonhuman primates suggest that the latter represent an appropriate animal model for the *in vivo* disposition of stavudine in humans. When ¹⁴C-radiolabeled stavudine was administered to monkeys as a single intravenous or oral dose, approximately 48% of the radioactivity was recovered in urine. The major component identified in monkey urine was unchanged stavudine, representing approximately 44% of the administered dose. Two putative metabolites identified in the urine were thymine (accounting for approximately 1% of the dose) and β -aminoisobutyric acid (accounting for approximately 2% of the dose). The metabolic fate of the deoxyribose moiety has not been investigated.

Special Populations and Conditions

Pediatrics

- **Pharmacokinetics in Children**

Stavudine pharmacokinetics have been evaluated in a subset of 25 HIV-infected pediatric patients (age range: 5 weeks to 15 years; weight range: 2 to 43 kg) after IV and oral administration of 0.125, 0.5, 1, and 2 mg/kg as single doses and as BID regimens. The mean absolute bioavailability was $76.9 \pm 31.7\%$ ($n = 20$). Peak plasma concentration (C_{max}) and area under the plasma concentration-time curve (AUC) increased in proportion to dose after both single and multiple doses.

- Absorption and Bioavailability in Children

Total exposure to stavudine, as reflected by mean steady-state AUC values, was comparable between pediatric patients receiving the usual recommended 2 mg/kg/day dose (1.439 $\mu\text{g}\cdot\text{hr}/\text{mL}$) and adults receiving 1 mg/kg/day dose (1.173 $\mu\text{g}\cdot\text{hr}/\text{mL}$).

- Distribution in Children

Following intravenous infusions (n = 14) of stavudine at doses ranging from 0.125 to 1 mg/kg, mean apparent volume of distribution ranged from 5.62 to 18.0 L (0.47 to 0.72 L/kg), suggesting that stavudine distributes into extravascular spaces. The distribution of stavudine into cerebrospinal fluid (CSF) was assessed in 8 pediatric patients after 12 weeks of multiple oral dosing. The concentration of stavudine in cerebrospinal fluid samples ranged from 0.008 to 0.105 $\mu\text{g}/\text{mL}$ at times ranging from 2 to 3 hours post-dose (dose ranging from 0.125 to 2 mg/kg). The cerebrospinal fluid concentrations ranged from 16% to 125% (mean \pm SD of 59% \pm 35%) of the concentration in simultaneous plasma samples.

- Elimination in Children

In 20 pediatric patients the mean \pm SD terminal elimination half-life was 0.96 \pm 0.26 hours after single oral doses (in adults with similar blood sampling, the half-life was 1.44 \pm 0.30 hours).

Renal Insufficiency

Data are available from two studies involving patients with renal insufficiency. One study recruited 15 non-HIV-infected subjects with reduced renal function and 5 subjects with normal renal function. The second study recruited 12 subjects with end-stage renal disease receiving maintenance hemodialysis; the pharmacokinetics of stavudine were determined between hemodialysis and at the time of a hemodialysis. The results of the two studies indicated that the apparent oral clearance (CL/F) of stavudine decreased and the terminal elimination half-life ($t_{1/2}$) increased as creatinine clearance (Cl_{cr}) decreased (refer to the table below). C_{max} and T_{max} were not significantly affected by reduced renal function. The mean \pm SD hemodialysis clearance value of stavudine was 120 \pm 18 mL/min; the mean \pm SD percentage of the stavudine dose recovered in the dialysate, timed to occur between 2-6 hours post-dose, was 31 \pm 5 percent. Based on these observations, it is recommended that ZERIT (stavudine) dosage be modified in patients with reduced creatinine clearance; in patients receiving maintenance hemodialysis it is recommended that stavudine be administered after the completion of a scheduled hemodialysis and at the same time of day on non-hemodialysis days (see DOSAGE and ADMINISTRATION).

**Mean ± SD Pharmacokinetic Values
Single 40 mg Oral Dose of Zerit**

	Creatinine Clearance			
	>50mL/min (n=10)	26-50 mL/min (n=5)	9-25 mL/min (n=5)	Dialysis Dependent†
Cl _{cr} (mL/min)	104 ± 28	41 ± 5	17 ± 3	NA
CL/F (mL/min)	335 ± 57	191 ± 39	116 ± 12	105± 17
CL _R (mL/min)	167 ± 65	73 ± 18	17 ± 3	NA
t _{1/2} (h)	1.7± 0.4	3.5±2.5	4.6 ± 0.9	5.4 ±1.4

CL_R = renal clearance; † = Off dialysis; NA = Not Applicable

Hepatic Insufficiency

Stavudine pharmacokinetics were not altered in 5 non-HIV infected patients with hepatic impairment secondary to cirrhosis following the administration of a single 40 mg dose.

MICROBIOLOGY

Stavudine has shown *in vitro* antiviral activity in HIV-infected T cell and monocyte/macrophage cultures. The drug concentration necessary to inhibit the cytopathic effects of HIV-1 infection by 50% (ED₅₀) in T cell cultures varied between 0.01 and 4.1 μM (0.002 to 0.91 μg/mL); the ED₅₀ in monocyte/macrophage cultures was 0.04 to 0.3 μM (0.009 to 0.07 μg/mL) as measured by p24 antigen production. Stavudine also inhibits HIV-2 replication in T cells *in vitro* as measured by plaque reduction with an ED₅₀ of 0.09 μM (0.02 μg/mL). *In vitro* sensitivity of HIV replication to stavudine varied over a 500-fold range depending on the assay conditions.

Activities of Stavudine Against HIV-1, HIV-2 and Cells

Cell type	Stavudine		
	ED ₅₀ (μ M)	CC ₅₀ (μ M)	TI
HIV-1			
MT-4 ¹	0.01	1.2	120
MT-4 ²	0.041	100	2400
MT-4 ⁹	0.05	19	380
ATH8 ³	4.1	110	27
CEM ⁴	0.15	90	600
Tall 1 ⁵	0.4		
PBMC ⁶	0.009 - 0.04	70	≥ 1750
M/M ⁷	0.04		
M/M ⁸	0.3		
HIV-2			
MT-4 ⁹	0.09		

ED₅₀ = Dose required for 50 percent inhibitory effect.
 CC₅₀ = Concentration required for 50 percent cytotoxicity.
 TI = Therapeutic Index = cell inhibition/ED₅₀ for virus
 μ M x 0.224 = μ g/mL.

As with other antiretroviral agents, a direct relationship has not been established between the *in vitro* inhibition of HIV replication and inhibition of HIV infection in humans or the clinical response to therapy.

Drug resistance

Preclinical studies: The potential for development of resistance to stavudine has been investigated *in vitro*. Selection studies performed with HIV 1 strains HXB2 and, IIIb have produced virus isolates with reduced (7- to 30-fold) sensitivity to stavudine.

Clinical studies: Limited phenotypic and genotypic resistance studies (20 paired HIV isolates) have shown that 4- to 12-fold decreases (3/20 isolates) in stavudine susceptibility are possible, however, the genetic bases for the observed susceptibility changes have not been identified. The clinical relevance of stavudine susceptibility changes has not been established.

Five of 11 stavudine post-treatment isolates (9 of which were from patients who had previously received zidovudine) developed moderate resistance (9- to 176-fold) to zidovudine and 3 of those 11 isolates developed moderate resistance (7- to 29-fold) to didanosine. The clinical relevance of these findings has not been established.

In three studies with human granulocyte/monocyte progenitor cells, stavudine was 20 to 100-fold less inhibitory than zidovudine. In one study using murine-derived granulocyte/monocyte progenitor cells, stavudine was 3 to 5-fold less inhibitory than zidovudine.

Stavudine has no significant antibacterial activity when tested against a panel of common pathogenic bacteria.

TOXICOLOGY

Extensive toxicity studies in laboratory animals have been conducted with stavudine, including evaluations for reproductive and genetic toxicities, at multiples of exposure up to approximately 400 times the human dose. No life-threatening toxicity was observed in pivotal safety studies of up to one year duration. Slight decreases in red blood cell indices, and hepatic alteration were the principal findings in rats and monkeys. Stavudine was not teratogenic and had no effect on mating or fertility. As with other nucleoside analogs and naturally occurring nucleosides, stavudine produced positive responses in one *in vivo* and two *in vitro* genetic toxicity assays. These positive findings occurred at relatively high concentrations and doses that resulted in high levels of exposure and probably reflect nucleotide metabolic disturbances rather than true genotoxic effects. For more detailed information, refer to the following tables.

Acute Toxicity

Species	Sex	Age (Weeks)	Route	Estimated Median Lethal Dose mg/kg	Pharmacotoxic Signs
Mouse	M F	5.5 - 6.5	Oral gavage	1000 - 2000	No clinical signs
Rat	M F	6	Oral gavage	882 - 2000 > 4000	Hypoactivity and ptosis
Rat	M F	6 days	Oral gavage	> 4000	No clinical signs
Rat	M F	3.5	Oral gavage	> 4000	No clinical signs
Rat	M F	6.5 - 7	Oral gavage	2000 - 4000	Hypoactivity
Monkey	M F	---	Oral nasogastric	> 2000	Emesis approximately 3 hours after dosing
Mouse	M F	6	I.V.	1000 - 2000	Hypoactivity at 2000 mg/kg
Rat	M F	6	I.V.	> 1200	Hypoactivity
Monkey	M F	---	I.V.	> 1680	Emesis and retching on the day of dosing

Subacute Toxicity

Species/ Strain	N/Dose	Sex	Route	Dosage Regimen (mg/kg/day)	Time	NOEL (No observed effect level)	Treatment Related Findings
Mouse/CD-1	10	M	Oral gavage	0, 100, 250, 500, 1000	4 weeks	100	<u>250 mg/kg</u> : Decrease in erythrocyte and leukocyte (lymphopenia) counts. <u>500 mg/kg</u> : Decrease in leukocyte count (lymphopenia) and increase in alanine aminotransferase. Grossly, yellow-tan foci on liver surface. Acute to chronic hepatic inflammation and hepatic multifocal necrosis. <u>1000 mg/kg</u> : Two deaths. Hypoactivity and labored respiration in one of these mice. Decrease in erythrocyte and leukocyte (neutropenia and lymphopenia) counts; increase in MCV, and alanine aminotransferase. Grossly, yellow-tan foci on liver surface. Acute to chronic hepatic inflammation, hepatic multifocal necrosis, and increase in number of hepatocellular intranuclear inclusions.
Rat/CD	5	M	Oral gavage	0, 100, 500, 1000	1 week	100	<u>500 mg/kg</u> : Slight hepatocellular hypertrophy. <u>1000 mg/kg</u> : Lymphoid depletion of thymus or spleen and hepatocellular hypertrophy.
Rat/CD	10 10	M F	Oral gavage	0, 100, 300, 600	1 month	100	<u>300 mg/kg</u> : Increase in liver weights (M). <u>600 mg/kg/day</u> : Increase in liver weights with centrilobular hypertrophy (M).
Rat/CD	15 15	M F	Oral gavage	0, 100, 300, 600	3 months	100	<u>300 mg/kg</u> : Increase in liver weights (M). <u>600 mg/kg</u> : Increase in liver weights (M & F) and centrilobular hepatocellular hypertrophy (M). Increases in adrenal and pituitary weights with no histopathologic correlates (M).
Monkey/ Cynomolgus	1 1	M F	Oral gavage	300 (M) 500 (F)	2 weeks	---	<u>300 mg/kg</u> : Slight decrease in hemogram (hematocrit, hemoglobin, and erythrocyte count) and transient increase in ALT. <u>500 mg/kg</u> : Decrease in food consumption. Slight decrease in hemogram (hematocrit, hemoglobin, and erythrocyte count). Transient increase in ALT and AST.
Monkey/ Cynomolgus	3 3	M F	Oral gavage	0, 60, 200, 600	1 month	200	<u>600 mg/kg</u> : Decrease in hemogram (erythrocyte count, hemoglobin, and hematocrit).
Monkey/ Cynomolgus	3 3	M F	Oral nasogas tric	0, 60, 200, 600	3 months	200	<u>600 mg/kg</u> : Decrease in hemogram (erythrocyte count, hematocrit, and hemoglobin). Increase in thyroid weight with no histopathologic correlate (F).
Rat/CD	10 10	M F	I.V.	0, 50, 300, 600	1 month	50	<u>300 and 600 mg/kg</u> : Increase in liver weights, enlarged livers, centrilobular hepatocellular hypertrophy.

Subacute Toxicity (cont'd)

Species/ Strain	N/Dose	Sex	Route	Dosage Regimen (mg/kg/day)	Time	NOEL (No observed effect level)	Treatment Related Findings
Monkey/ Cynomolgus	1 1	M F	I.V.	0, 50, 200, 400	2 weeks		<u>50 mg/kg</u> : Decreased food consumption. <u>400 mg/kg</u> : Decrease in food consumption, hemogram (erythrocyte count, hematocrit, hemoglobin) and leukocyte count (neutropenia). Deposition of yellow-brown pigment in small clusters of hepatic macrophages, erythrophagocytosis and hemosiderosis in lymph nodes, and thymic lymphoid depletion.
Monkey/ Cynomolgus	2 2	M F	I.V.	0, 25, 100, 400	1 month	100	<u>400 mg/kg</u> : Increase in ALT in 1M on day 28.

Chronic Toxicity

Species/ Strain	N/Dose	Sex	Route	Dosage Regimen (mg/kg/day)	Time	NOEL (No observed effect level)	Treatment Related Findings
Rat/CD	35 35	M F	Oral gavage	0, 100, 300, 600	1 year & 3 month recovery	100	<p><u>300 mg/kg</u>: Reversible decrease in erythrocyte counts. Reversible liver alterations consisting of increased weights (M,F) correlated with centrilobular hepatocellular hypertrophy (M) pale discoloration (M,F) with multifocal hepatocellular vacuolation (M) and increase in incidence of foci of cytologic alteration (M).</p> <p><u>600 mg/kg</u>: Increase in incidence of soiled hair coat. Partially reversible decrease in hematocrit and erythrocyte counts. Reversible liver alterations consisting of increased weights with centrilobular hepatocellular hypertrophy and proliferation of smooth endoplasmic reticulum, pale discoloration correlated with hepatocellular cytoplasmic vacuolation (M) and increase in incidence of foci of cytologic alteration.</p>
Monkey/ Cynomolgu s	5 5	M F	Oral nasoga stric	0, 60, 200, 600	1 year & 3 month recovery	60	<p><u>200 mg/kg</u>: Reversible increase in liver weight (M).</p> <p><u>600 mg/kg</u>: Reversible increase in mean liver weights and accompanying centrilobular hepatocellular hypertrophy with minimal to mild proliferation of smooth endoplasmic reticulum.</p>

Reproduction and Teratology

Species/ Strain	N/ Group	Sex	Route	Dosage mg/kg/day	Time	Findings
SEGMENT I						
Rat/CD	24 24	M F	Oral gavage	0, 100, 300, 600	<u>Males:</u> dosing 63 days prior to and during mating. <u>Females:</u> 12/group, dosing 14 days prior to and during mating and throughout gestation and lactation; 12/group, dosing 14 days prior to and during mating and up to Day 20 of gestation.	<u>600 mg/kg:</u> Liver enlargement and/or increase in liver weights in F ₀ (M,F) (Caesarean section). Decrease in uterine weights of F ₀ (F) (Caesarean section). A slight post-implantation loss was noted in F ₀ (F). A slight decrease in group mean body weights of F ₁ (M) during pre-mating period.
SEGMENT II						
Rat/CD	25	F	Oral gavage	0, 50, 250, 1000	Dosing on Day 6 through 17 of gestation.	<u>1000 mg/kg:</u> Increased fetal incidence of unossified/ incomplete ossification of sternebra.
Rabbit/ New Zealand White	3	F	Oral gavage	0, 60, 150, 300, 600	Dosing on Day 6 through 18 of gestation (once daily).	None
Rabbit/ New Zealand White	3	F	Oral gavage	0, 60, 150, 300, 600	Dosing on Day 6 through 18 of gestation (twice daily).	<u>600 mg/kg:</u> Body weight loss and decreased food consumption in one pregnant doe.
Rabbit/ New Zealand White	18	F	Oral gavage	0, 60, 300, 600	Dosing on Day 6 through 18 of gestation.	None
SEGMENT III						
Rat/SD	22	F	Oral gavage	0, 50, 250, 1000	Dosing on Day 17 of gestation through 21 days after parturition.	<u>1000 mg/kg:</u> Increase in liver weights in F ₀ dams. Increase in postnatal mortality (birth to postnatal day 4) in F ₁ neonates.

Carcinogenicity and Mutagenicity

In 2-year carcinogenicity studies in mice and rats, stavudine was noncarcinogenic at doses which produced exposures (AUC) 39 and 168 times, respectively, the recommended clinical dose for humans. Benign and malignant liver tumors in mice and rats and malignant urinary bladder tumors in male rats occurred only at higher levels of exposure, 250 (mice) and 732-1785 (rats) times human exposure at the recommended clinical dose.

In the rat doses of 100, 600 and 4000 mg/kg/day were selected for the carcinogenicity study based on hepatic changes at 4000 mg/kg/day in the range-finding study. The high dose of 4000 mg/kg/day was reduced to 2000 mg/kg/day after 16 weeks of dosing due to mortality and hepatocellular injury. Interim data from the ongoing study indicate that possible drug-related finding of cholangio-carcinomas in the liver and transitional cell carcinomas of the urinary bladder at the high dose have been observed up through 18 months of dosing, while these neoplasms have not been seen at the lower doses. Exposures to stavudine in rats at the high dose are 718 - 1750 times the exposure observed in humans at the recommended dose.

Results from the genetic toxicity studies suggest that stavudine is genotoxic only at exposures greatly exceeding those occurring in clinical trials and are comparable to results seen with other nucleoside analogues and with the naturally-occurring DNA nucleoside thymidine. Stavudine was not mutagenic in the Ames, *E. coli* reverse mutation, or the CHO/HGPRT mammalian cell forward gene mutation assays with and without metabolic activation. Stavudine produced positive results in the *in vitro* human lymphocyte clastogenesis and mouse fibroblast assays and in the *in vivo* mouse micronucleus test. In the *in vitro* assays, stavudine elevated the frequency of chromosome aberrations in human lymphocytes (concentrations 25 to 250 µg/mL, without metabolic activation) and increased the frequency of transformed foci in mouse fibroblast cells (concentrations of 25 to 2500 µg/mL, with and without metabolic activation). In the *in vivo* micronucleus assay, stavudine was clastogenic in bone marrow cells following oral administration to mice at dosages of 600 to 2000 mg/kg/day for 3 days. The lowest concentration (25 µg/mL) producing positive responses in the *in vitro* assays was approximately 38 times higher than the C_{MAX} and 250 times higher than the average stavudine plasma concentration over 12 hours in humans receiving one-half the total daily clinical dose of 1 mg/kg. The positive response in the mouse micronucleus test occurred at dosages which produced mortalities and resulted in exposures estimated to be at least 110 times greater than those seen clinically at 1 mg/kg. Zidovudine and zalcitabine produce similarly positive results in this assay.

REFERENCES

1. August EM, Marongiu ME, Lin T-S, Prusoff WH
Initial studies on the cellular pharmacology of 3'-deoxythymidin-2'-ene (d4T): a potent and selective inhibitor of human immunodeficiency virus
Biochem Pharmacol 37:4419-4422, 1988
2. Balzarini J, Herdewijn P, De Clercq E
Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds
J Biol Chem 262:6127-6133, 1989
3. Browne MJ, Mayer KH, Chafee SBD, *et al.*
2',3'-Didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial
The Journal of Infectious Diseases 167:21-29, 1993
4. Cameron DW, Heath-Chiozzi M, Danner S, *et al.*
Randomized placebo-controlled trial of zidovudine in advanced HIV-1 disease.
Lancet 1998;351:543-549.
5. Carpenter CCJ, Fischl MA, Hammer SM, *et al.*
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA Panel.
JAMA 1997;277:1962-1969.
6. Cretton EM, Zhou Z, Kidd LB, *et al.*
In vitro and *in vivo* Disposition and Metabolism of 3'-deoxy-2',3'-didehydrothymidine
Antimicrobial Agents and Chemotherapy 37(9):1816-1825, 1993.
7. Dudley MN, Graham KK, Kaul S, *et al.*
Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex
The Journal of Infectious Diseases 166:480-485, 1992
8. Hitchcock MJM
2',3'-Didehydro-2',3'-dideoxythymidine (d4T), an anti-HIV agent
Antiviral Chemistry & Chemotherapy 2(3):125-132, 1991
9. Ho H-T, Hitchcock MJM
Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus
Antimicrob Agents Chemother 33:844-849, 1989

10. Huang P, Farquhar D, Plunkett W
Selective action of 2',3'-didehydro-2',3'-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases
J Biol Chem 267:2817-2822, 1992
11. Kaul S and Dandekar KA
Pharmacokinetics of the anti-human immunodeficiency virus nucleoside analog stavudine in cynomolgus monkeys
Antimicrobial Agents and Chemotherapy 37(9):1816-1825, 1993
12. Lin T-S, Schinazi RF, Prusoff WH
Potent and selective *in vitro* activity of 3'-deoxythymidine-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus
Biochem Pharmacol 36:2713-2718, 1987
13. Russell JW, Whiterock VJ, Marrero D and Klunk L
Disposition in animals of a new anti-HIV agent: 2',3'-didehydro-3'-deoxythymidine
Drug Metab and Disp 18:153-157, 1990
14. Schinazi RF, Boudinot FD, Doshi KJ and McClure HM
Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys
Antimicrobial Agents and Chemotherapy 34(6):1214-1219, 1990
15. Sidwell RW, Okleberry KJ, Burger RA, Warren RP, Morrey JD
Suppression of murine retroviral disease as a model for AIDS by 2',3'-dideoxy-2',3'-didehydrothymidine (d4T)
Antiviral Res 17(S1):132, 1992

PART III: CONSUMER INFORMATION

Pr **ZERIT**
Stavudine

This leaflet is Part III of a three-part “Product Monograph” published when ZERIT was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about ZERIT. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for

ZERIT (Pronounced ZER it) is a prescription medicine used in combination with other drugs to treat adults and children who are infected with HIV (the human immunodeficiency virus), the virus that causes AIDS.

What it does

ZERIT belongs to a class of drugs called nucleoside analogues. By reducing the growth of HIV, ZERIT helps your body maintain its supply of CD4 cells, which are important for fighting HIV and other infections.

ZERIT will not cure your HIV infection. At present there is no cure for HIV infection. Even while taking ZERIT, you may continue to have HIV-related illnesses, including infections caused by other disease-producing organisms. Continue to see your doctor regularly and report any medical problems that occur. Inform your doctor of all your medical conditions such as liver disease, diabetes, or if you are taking other medications. Do not take any medicine, vitamin, supplement, or other health preparation without first checking with your doctor.

ZERIT does not prevent a patient infected with HIV from passing the virus to other people. To protect others, you must continue to practice safe sex and take precautions to prevent others from coming in contact with your blood and other body fluids.

The long-term effects of ZERIT are unknown at this time.

When it should not be used

Do not take ZERIT if you are allergic to any of its ingredients, including its active ingredient, stavudine, and the inactive ingredients. (See “What the nonmedicinal ingredients are” in this leaflet). Tell your doctor if you think you have had an allergic reaction to any of these ingredients.

What the medicinal ingredient is:
Stavudine

What the nonmedicinal ingredients are:
ZERIT Capsules: lactose (milk sugar), magnesium stearate, microcrystalline cellulose, sodium starch glycolate.
Capsule shell: gelatin, black iron oxide (20 mg only), printing ink, silicon dioxide, sodium lauryl sulphate, titanium dioxide and yellow and red iron oxides.

What dosage forms it comes in:
Capsules: 15, 20, 30 and 40 mg

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

Lactic acidosis and severe liver enlargement - Lactic acidosis (severe increase of lactic acid in the blood) and severe liver enlargement, including deaths, have been reported among patients taking ZERIT. Symptoms of lactic acidosis may include:

- nausea, vomiting, or unusual or unexpected stomach discomfort;
- feeling very weak and tired;
- shortness of breath;
- weakness in arms and legs.

If you notice these symptoms or if your medical condition has suddenly changed, stop taking ZERIT and call your doctor right away. Lactic acidosis is a medical emergency that must be treated in a hospital.

See “SIDE EFFECTS AND WHAT TO DO ABOUT THEM”.

Talk to your doctor before using ZERIT if:

- You are using other medications including those you can buy without a prescription, as they may interfere with ZERIT (See Interactions with this medication).

- **You are pregnant or planning on becoming pregnant.** It is not known if ZERIT can harm a human fetus. Also, pregnant women have experienced serious side effects when taking ZERIT in combination with didanosine and other HIV medicines. ZERIT should be used during pregnancy only after discussion with your doctor.
- **You are breastfeeding.** Studies have shown ZERIT is in the breast milk of animals receiving the drug, so it may be present in human breast milk. The Centers for Disease Control and Prevention (CDC) recommends that HIV-infected mothers **not** breast-feed to reduce the risk of passing HIV infection to their babies and the potential for serious adverse reactions in nursing infants. Therefore, do not nurse a baby while taking ZERIT.
- You have kidney, liver problems or history of heavy alcohol use.
- You have had pancreatitis, gallstones.
- You have had peripheral neuropathy.

INTERACTIONS WITH THIS MEDICATION

Other medicines, including those you can buy without a prescription, may interfere with the actions of ZERIT. You should not use ZERIT in combination with zidovudine (AZT). You should talk to your doctor if you are taking doxorubicin or ribavirin as these drugs may interfere with ZERIT. Do not take any medicine, vitamin, supplement, or other health preparation without first checking with your doctor. (Taking ZERIT with other drugs that also may cause peripheral neuropathy may increase your risk of getting this serious side effect.)

PROPER USE OF THIS MEDICATION

Usual dose

Your doctor will determine your dose (the amount in each capsule) based on your body weight, kidney and liver function, and any side effects that you may have had with other medicines. Take ZERIT exactly as instructed. **ZERIT may be taken with food or on an empty stomach.**

Capsules: ZERIT capsules are usually taken twice a day (every 12 hours).

If you have a kidney problem: If your kidneys are not working properly, your doctor may monitor your kidney function while you take ZERIT. Also, your dosage of ZERIT may be adjusted.

Overdose

In case of drug overdosage, contact a healthcare practitioner (e.g. doctor) hospital emergency department or regional poison control centre, even if there are no symptoms.

Missed Dose

Try not to miss a dose, but if you do, take it as soon as possible. If it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not double doses.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Serious side effects of ZERIT may include:

- **Lactic acidosis**, severe increase of lactic acid in the blood, **severe liver enlargement**, including inflammation (pain and swelling) of the liver, and **liver failure**, which can cause death.
- **Peripheral neuropathy**, a nerve disorder of the hands and feet.

People who take ZERIT along with other medicines that may cause similar side effects may have a higher chance of developing these side effects than if they took ZERIT alone. For example, if you use ZERIT in combination with other drugs (including didanosine) that may be associated with liver enlargement, peripheral neuropathy, or pancreatitis, you may be at increased risk for these side effects. Children experience side effects that are similar to those experienced by adults.

Lactic acidosis and severe liver enlargement - Lactic acidosis and severe liver enlargement, including deaths, have been reported among patients taking ZERIT. Symptoms of lactic acidosis may include:

- nausea, vomiting, or unusual or unexpected stomach discomfort;
- feeling very weak and tired;
- shortness of breath;
- weakness in arms and legs.

If you notice these symptoms or if your medical condition

has suddenly changed, stop taking ZERIT and call your doctor right away. Lactic acidosis is a medical emergency that must be treated in a hospital. Women, overweight patients, and those who have had lengthy treatment with nucleoside medicines are more likely to develop lactic acidosis. Your doctor should check your liver function periodically while you are taking ZERIT, especially if you have a history of heavy alcohol use or a liver problem. The combination of ZERIT and didanosine may increase your risk for liver damage, which may be fatal. Your doctor should closely monitor your liver function if you are taking this combination.

Fat redistribution - Changes in body fat have been seen in some patients taking antiretroviral therapy. These changes may include increased amount of fat in the upper back and neck (“buffalo hump”), breasts, and around the trunk. Loss of fat from the legs, arms, and face may also happen. The cause and long-term health effects of these conditions are not known at this time.

Peripheral neuropathy - This nerve disorder is rare, but may be serious. **Tell your doctor right away** if you or a child taking ZERIT has continuing numbness, tingling, burning, or pain in the feet and/or hands. A child may not recognize these symptoms or know to tell you that his or her feet or hands are numb, burning, tingling, or painful. Ask your child's doctor for instructions on how to find out if your child develops peripheral neuropathy.

Let your doctor know if you or a child taking ZERIT has ever had peripheral neuropathy, because this condition occurs more often in patients who have had it previously. Peripheral neuropathy is also more likely to occur in patients taking drugs that affect the nerves and in patients with advanced HIV disease, but it can occur at any disease stage. If you develop peripheral neuropathy, your doctor may tell you to stop taking ZERIT. In some cases the symptoms worsen for a short time before getting better. Once symptoms of peripheral neuropathy go away completely, your doctor may decide to start ZERIT again at a lower dose.

Pancreatitis - Pancreatitis is a dangerous inflammation of the pancreas. It may cause death. **Tell your doctor right away if you develop stomach pain, nausea, or vomiting. These can be signs of pancreatitis.** Let your doctor know if you have ever had pancreatitis, regularly drink alcoholic beverages, or have gallstones. Pancreatitis occurs more often in patients with these conditions. It is also more likely in people with advanced HIV disease, but can occur at any disease stage. The combination of ZERIT and didanosine, with or without hydroxyurea, may increase your risk for pancreatitis.

Other side effects - In addition to peripheral neuropathy,

the most frequent side effects observed in studies of adults taking the recommended dose of ZERIT were headache, diarrhea, rash, and nausea and vomiting. Other side effects may include abdominal pain, muscle pain, insomnia, loss of appetite, chills or fever, allergic reactions, blood disorders.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM			
Symptom / effect	Talk with your doctor right away		Stop taking drug and call your doctor
	Only if severe	In all cases	
nausea, vomiting, unusual or unexpected stomach discomfort, feeling very weak and tired, shortness of breath, weakness in arms and legs, sudden unexplained weight loss (these can be a sign of lactic acidosis or severe liver enlargement)			✓
stomach pain, nausea, vomiting (these can be a sign of pancreatitis)		✓	
numbness, tingling, burning or pain in the feet and/or hands (these can be a sign of peripheral neuropathy)		✓	

This is not a complete list of side effects. For any unexpected effects while taking ZERIT, contact your doctor or pharmacist.

HOW TO STORE IT

ZERIT capsules should be stored at room temperature (15° to 30°C) and protected from excessive moisture. Do NOT store this medicine in a damp place such as a bathroom medicine cabinet or near the kitchen sink. Keep bottles tightly closed and out of the reach of children and pets.

This medicine was prescribed for your particular condition. Do not use ZERIT for another condition or give it to others. Keep ZERIT and all other medicines out of the reach of children. Please return all unused medication to the pharmacist for proper disposal.

This summary does not include everything there is to know about ZERIT. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. If you have questions or concerns, or want more information about ZERIT, your physician and pharmacist have the complete prescribing information upon which this leaflet was based. You may want to

read it and discuss it with your doctor or other healthcare professional. Remember, no written summary can replace careful discussion with your doctor.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
 - Fax toll-free to 1-866-678-6789, or
 - Mail to: Canada Vigilance Program
Health Canada
Postal Locator 0701C
Ottawa, ON K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reactions reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

Note: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

For more information or for the full Product Monograph on ZERIT, contact the sponsor, Bristol-Myers Squibb, at: 1-866-463-6267.

This leaflet was prepared by Bristol-Myers Squibb.

Last revised: August 5, 2010